A cross sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA study.

TY - JOUR

T1 - A cross sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA study.

AU - Millgate, Ed

AU - Kravariti, Jenny

AU - Egerton, Alice

AU - Howes, Oliver

AU - Murray, Sir Robin M

AU - Kassoumeri, Laura

AU - Donocik, Jacek

AU - Lewis, Shôn W.

AU - Drake, Richard

AU - Lawrie, Stephen

AU - Murphy, Anna

AU - Collier, Tracy

AU - Lees, Jane

AU - Stockton-Powdrell, Charlotte

AU - Walters, James

AU - Deakin, Bill

AU - Maccabe, James

PY - 2021/11/25

Y1 - 2021/11/25

N2 - Background: 70-84% of individuals with antipsychotic treatment resistance show non-response (NR) from the first episode. Emerging cross-sectional evidence comparing cognitive profiles in treatment resistant schizophrenia to treatment-responsive schizophrenia has indicated that verbal memory and language functions may be more impaired in treatment resistance. We sought to confirm this finding by comparing cognitive performance between antipsychotic non-responders (NR) and responders (R) using a brief cognitive battery for schizophrenia, with a primary focus on verbal tasks compared against other measures of cognition. Design: Cross-sectional Setting: This cross-sectional study recruited antipsychotic treatment responders (R) and antipsychotic non-responders (NR) across four UK sites. Cognitive performance was assessed using the Brief Assessment of Cognition in Schizophrenia (BACS).Participants: One hundred and six participants aged 18 – 65 years with a diagnosis of schizophrenia or schizophreniform disorder were recruited according to their treatment response, with 52 NR, and 54 R cases. Outcomes: Composite and subscale scores of cognitive performance on the BACS. Group (R vs NR) differences in cognitive scores were investigated using univariable and multivariable linear regressions adjusted for age, gender and illness duration. Results: Univariable regression models observed no significant differences between R and NR groups on any measure of the BACS, including verbal memory (95% CI -6.63 to 2.66, p = .398) and verbal fluency (95% CI -2.46 to 4.91, p = .510). This pattern of findings was consistent in multivariable models. Conclusions: The lack of group difference in cognition in our sample is likely due to a lack of clinical distinction between our groups. Future investigations should aim to utilise machine learning methods using longitudinal first episode samples to identify responder subtypes within schizophrenia, and how cognitive factors may interact within this.Trail registration number: REC: 15/LO/0038. Keywords: cognition, treatment resistance, antipsychotic response, schizophrenia, BACS

AB - Background: 70-84% of individuals with antipsychotic treatment resistance show non-response (NR) from the first episode. Emerging cross-sectional evidence comparing cognitive profiles in treatment resistant schizophrenia to treatment-responsive schizophrenia has indicated that verbal memory and language functions may be more impaired in treatment resistance. We sought to confirm this finding by comparing cognitive performance between antipsychotic non-responders (NR) and responders (R) using a brief cognitive battery for schizophrenia, with a primary focus on verbal tasks compared against other measures of cognition. Design: Cross-sectional Setting: This cross-sectional study recruited antipsychotic treatment responders (R) and antipsychotic non-responders (NR) across four UK sites. Cognitive performance was assessed using the Brief Assessment of Cognition in Schizophrenia (BACS).Participants: One hundred and six participants aged 18 – 65 years with a diagnosis of schizophrenia or schizophreniform disorder were recruited according to their treatment response, with 52 NR, and 54 R cases. Outcomes: Composite and subscale scores of cognitive performance on the BACS. Group (R vs NR) differences in cognitive scores were investigated using univariable and multivariable linear regressions adjusted for age, gender and illness duration. Results: Univariable regression models observed no significant differences between R and NR groups on any measure of the BACS, including verbal memory (95% CI -6.63 to 2.66, p = .398) and verbal fluency (95% CI -2.46 to 4.91, p = .510). This pattern of findings was consistent in multivariable models. Conclusions: The lack of group difference in cognition in our sample is likely due to a lack of clinical distinction between our groups. Future investigations should aim to utilise machine learning methods using longitudinal first episode samples to identify responder subtypes within schizophrenia, and how cognitive factors may interact within this.Trail registration number: REC: 15/LO/0038. Keywords: cognition, treatment resistance, antipsychotic response, schizophrenia, BACS

KW - cognition

KW - treatment resistance

KW - antipsychotic response

KW - schizophrenia

KW - BACS

M3 - Article

SN - 2044-6055

JO - BMJ Open

JF - BMJ Open

ER -